Video
Dr. Eric Klein discusses how IsoPSA works for prostate cancer risk assessment
Author(s):
“IsoPSA is a way of measuring all the different PSA-related proteins in the blood,” says Eric A. Klein, MD.
Video Player is loading.
In this video, Eric A. Klein, MD, provides an overview of the IsoPSA test and how it works. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Study results affirm effectiveness of evolving prostate cancer therapies
Related Content
